Healthcare provider profile · identity verified

Junwei Liu

Internal Medicine · SUMMIT, WI · NPI 1275832875

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	713	204
Losartan Potassium	Losartan Potassium	604	161
Amlodipine Besylate	Amlodipine Besylate	603	167
Levothyroxine Sodium	Levothyroxine Sodium	360	91
Lisinopril	Lisinopril	336	93
Metoprolol Succinate	Metoprolol Succinate	324	92
Pravastatin Sodium	Pravastatin Sodium	314	84
Hydrochlorothiazide	Hydrochlorothiazide	272	84
Omeprazole	Omeprazole	256	80
Tamsulosin Hcl	Tamsulosin Hcl	224	65
Metformin Hcl	Metformin Hcl	221	64
Simvastatin	Simvastatin	219	58
Metformin Hcl Er	Metformin Hcl	188	52
Pantoprazole Sodium	Pantoprazole Sodium	184	59
Gabapentin	Gabapentin	165	49
Rosuvastatin Calcium	Rosuvastatin Calcium	164	48
Furosemide	Furosemide	158	49
Metoprolol Tartrate	Metoprolol Tartrate	142	40
Glimepiride	Glimepiride	137	34
Allopurinol	Allopurinol	126	35
Carvedilol	Carvedilol	101	28
Albuterol Sulfate Hfa	Albuterol Sulfate	99	43
Januvia	Sitagliptin Phosphate	95	26
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	95	26
Atenolol	Atenolol	94	29
Fluticasone Propionate	Fluticasone Propionate	92	30
Potassium Chloride	Potassium Chloride	87	22
Sertraline Hcl	Sertraline Hcl	83	26
Trazodone Hcl	Trazodone Hcl	81	23
Clopidogrel	Clopidogrel Bisulfate	80	23
Alendronate Sodium	Alendronate Sodium	77	22
Warfarin Sodium	Warfarin Sodium	77	14
Eliquis	Apixaban	68	19
Famotidine	Famotidine	67	30
Jardiance	Empagliflozin	61	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	61	14
Valsartan	Valsartan	59	19
Escitalopram Oxalate	Escitalopram Oxalate	55	17
Clonazepam	Clonazepam	51	11
Lovastatin	Lovastatin	51	15
Duloxetine Hcl	Duloxetine Hcl	50	15
Spironolactone	Spironolactone	50	16
Buspirone Hcl	Buspirone Hcl	49	14
Ezetimibe	Ezetimibe	48	15
Tramadol Hcl	Tramadol Hcl	47	11
Hydralazine Hcl	Hydralazine Hcl	46	suppressed
Nifedipine Er	Nifedipine	46	13
Alprazolam	Alprazolam	45	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	45	suppressed
Ozempic	Semaglutide	42	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	39	suppressed
Ropinirole Hcl	Ropinirole Hcl	39	suppressed
Irbesartan	Irbesartan	37	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	37	13
Montelukast Sodium	Montelukast Sodium	36	12
Glipizide Er	Glipizide	35	suppressed
Celecoxib	Celecoxib	34	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	34	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	34	suppressed
Benazepril Hcl	Benazepril Hcl	31	suppressed
Fenofibrate	Fenofibrate	31	suppressed
Finasteride	Finasteride	31	suppressed
Glipizide	Glipizide	31	11
Synthroid	Levothyroxine Sodium	31	11
Tizanidine Hcl	Tizanidine Hcl	31	12
Citalopram Hbr	Citalopram Hydrobromide	29	12
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	25
Amoxicillin	Amoxicillin	26	19
Mirtazapine	Mirtazapine	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Xarelto	Rivaroxaban	23	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Baclofen	Baclofen	19	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	19	suppressed
Midodrine Hcl	Midodrine Hcl	19	suppressed
Ramipril	Ramipril	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Prednisone	Prednisone	18	11
Humalog Kwikpen U-100	Insulin Lispro	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Dutasteride	Dutasteride	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	16	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Lamotrigine	Lamotrigine	15	suppressed
Mupirocin	Mupirocin	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Anastrozole	Anastrozole	14	suppressed
Cephalexin	Cephalexin	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Torsemide	Torsemide	14	suppressed
Dilt-Xr	Diltiazem Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	13
Doxycycline Monohydrate	Doxycycline Monohydrate	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Nystatin	Nystatin	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Bupropion Hcl	Bupropion Hcl	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Cholestyramine	Cholestyramine (With Sugar)	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error